Mallinckrodt pain drug Xartemis hit with 3 month delay
This article was originally published in Scrip
Executive Summary
Shares of Mallinckrodt were bruised on 25 November, falling 4.4%, on word the FDA had delayed by three months its decision on the company's new drug application (NDA) for Xartemis XR (oxycodone hydrochloride and acetaminophen) as a treatment to manage moderate to severe acute pain where the use of an opioid analgesic is appropriate.